Products - Blood conditions | Topic

Showing 82 products

Date | Title

ABP 959 (eculizumab biosimilar) for treating paroxysmal nocturnal haemoglobinuria [TSID10250]
Status:
Topic selection
Programme:
Technology appraisal guidance
Expected publication date:
TBC
Active B12 assay for diagnosing vitamin B12 deficiency (MIB40)
Product type:
Advice
Programme:
Medtech innovation briefing
Published:
30 September 2015
Andexanet alfa for reversing anticoagulation from apixaban or rivaroxaban (TA697)
Product type:
Guidance
Programme:
Technology appraisal guidance
Last updated:
15 January 2025
Published:
12 May 2021
Andexanet alfa for reversing anticoagulation in people with intracranial haemorrhage (terminated appraisal) (TA1029)
Product type:
Guidance
Programme:
Technology appraisal guidance
Published:
15 January 2025
Apadamtase alfa for preventing and treating congenital thrombotic thrombocytopenic purpura caused by ADAMTS-13 deficiency [ID6192]
Status:
Awaiting development
Programme:
Technology appraisal guidance
Expected publication date:
TBC
Autoimmune haemolytic anaemia: rituximab (ESUOM39)
Product type:
Advice
Programme:
Evidence summary
Published:
10 February 2015
Avapritinib for treating moderate to severe symptoms of indolent systemic mastocytosis [ID12202]
Status:
Awaiting development
Programme:
Technology appraisal guidance
Expected publication date:
TBC
Avatrombopag for treating primary chronic immune thrombocytopenia (TA853)
Product type:
Guidance
Programme:
Technology appraisal guidance
Published:
15 December 2022
Avatrombopag for treating primary chronic immune thrombocytopenia in people 1 to 17 years [TSID12109]
Status:
Topic selection
Programme:
Technology appraisal guidance
Expected publication date:
TBC
Benralizumab for treating hypereosinophilic syndrome in people 12 years and over [ID6322]
Status:
Awaiting development
Programme:
Technology appraisal guidance
Expected publication date:
TBC
Berotralstat for preventing recurrent attacks of hereditary angioedema in children aged 2 to 12 years [TSID 12132]
Status:
Topic selection
Programme:
Technology appraisal guidance
Expected publication date:
TBC
Budesonide (Jorveza) for maintaining remission of eosinophilic oesophagitis in people 2 years and over [ID6486]
Status:
Awaiting development
Programme:
Technology appraisal guidance
Expected publication date:
TBC
Canakinumab for untreated Schnitzler syndrome [ID4063]
Status:
Topic selection
Programme:
Technology appraisal guidance
Expected publication date:
TBC
Caplacizumab with plasma exchange and immunosuppression for treating acute acquired thrombotic thrombocytopenic purpura (TA667)
Product type:
Guidance
Programme:
Technology appraisal guidance
Published:
16 December 2020
Concizumab for preventing bleeding episodes in haemophilia A or haemophilia B [ID5099]
Status:
Awaiting development
Programme:
Technology appraisal guidance
Expected publication date:
TBC
Crizanlizumab for preventing recurrent vaso-occlusive crises in sickle cell disease in young people aged 12 to 17 [TSID10766]
Status:
Topic selection
Programme:
Technology appraisal guidance
Expected publication date:
TBC
Crovalimab for treating paroxysmal nocturnal haemoglobinuria in people 12 years and over (TA1019)
Product type:
Guidance
Programme:
Technology appraisal guidance
Published:
20 November 2024
Danicopan with ravulizumab or eculizumab for treating paroxysmal nocturnal haemoglobinuria (TA1010)
Product type:
Guidance
Programme:
Technology appraisal guidance
Published:
23 October 2024
Daprodustat for treating anaemia in people with chronic kidney disease [ID3987]
Status:
In development
Programme:
Technology appraisal guidance
Expected publication date:
TBC
Donidalorsen for preventing hereditary angioedema attacks in people 12 years and over [ID6457]
Status:
In development
Programme:
Technology appraisal guidance
Expected publication date:
TBC
Dupilumab for treating eosinophilic oesophagitis in children 1 to 11 years [ID6492]
Status:
Awaiting development
Programme:
Technology appraisal guidance
Expected publication date:
TBC
Eculizumab for treating atypical haemolytic uraemic syndrome (HST1)
Product type:
Guidance
Programme:
Highly specialised technologies guidance
Published:
28 January 2015
Efanesoctocog alfa for treating and preventing bleeding episodes in haemophilia A in people 2 years and over (TA1051)
Product type:
Guidance
Programme:
Technology appraisal guidance
Published:
2 April 2025
Eltrombopag for treating chronic immune thrombocytopenia (TA293)
Product type:
Guidance
Programme:
Technology appraisal guidance
Last updated:
26 October 2018
Published:
24 July 2013
Eltrombopag for treating severe aplastic anaemia refractory to immunosuppressive therapy (terminated appraisal) (TA382)
Product type:
Guidance
Programme:
Technology appraisal guidance
Published:
27 January 2016
Emicizumab for preventing bleeding episodes in people with mild or moderate haemophilia A [ID5098]
Status:
Topic selection
Programme:
Technology appraisal guidance
Expected publication date:
TBC
Erythropoiesis‑stimulating agents (epoetin and darbepoetin) for treating anaemia in people with cancer having chemotherapy (TA323)
Product type:
Guidance
Programme:
Technology appraisal guidance
Published:
26 November 2014
Etranacogene dezaparvovec for treating moderately severe or severe haemophilia B (TA989)
Product type:
Guidance
Programme:
Technology appraisal guidance
Published:
24 July 2024
Exagamglogene autotemcel for treating severe sickle cell disease in people 12 years and over (TA1044)
Product type:
Guidance
Programme:
Technology appraisal guidance
Published:
26 February 2025
Exagamglogene autotemcel for treating transfusion-dependent beta-thalassaemia in people 12 years and over (TA1003)
Product type:
Guidance
Programme:
Technology appraisal guidance
Published:
11 September 2024
Ferric maltol for treating iron deficiency anaemia in children and adolescents aged 1 month to 17 years TS ID 11994
Status:
Topic selection
Programme:
Technology appraisal guidance
Expected publication date:
TBC
Fidanacogene elaparvovec for treating moderately severe to severe haemophilia B [ID4032]
Status:
In development
Programme:
Technology appraisal guidance
Expected publication date:
TBC
Fostamatinib for treating refractory chronic immune thrombocytopenia (TA835)
Product type:
Guidance
Programme:
Technology appraisal guidance
Published:
19 October 2022
Garadacimab for preventing recurrent attacks of hereditary angioedema in people 12 years and over [ID6394]
Status:
In development
Programme:
Technology appraisal guidance
Expected publication date:
21 August 2025
Giroctocogene fitelparvovec for treating moderately severe to severe haemophilia A ID6312
Status:
In development
Programme:
Technology appraisal guidance
Expected publication date:
TBC
Gout
Status:
Awaiting development
Expected publication date:
TBC
Helge for detecting haemolysis
Status:
Topic selection
Programme:
Diagnostics guidance
Expected publication date:
TBC
Immune (idiopathic) thrombocytopenic purpura: rituximab (ESUOM35)
Product type:
Advice
Programme:
Evidence summary
Published:
21 October 2014
Inclacumab for preventing recurrent vaso-occlusive crises in sickle cell disease in people 16 years and over [ID6551]
Status:
Awaiting development
Programme:
Technology appraisal guidance
Expected publication date:
TBC
Iptacopan for treating paroxysmal nocturnal haemoglobinuria (TA1000)
Product type:
Guidance
Programme:
Technology appraisal guidance
Published:
4 September 2024
Jaundice in newborn babies under 28 days (CG98)
Product type:
Guidance
Programme:
Clinical guideline
Last updated:
31 October 2023
Published:
19 May 2010
Jaundice in newborn babies under 28 days (QS57)
Product type:
Quality standard
Published:
6 March 2014
Luspatercept for treating anaemia caused by beta-thalassaemia (terminated appraisal) (TA843)
Product type:
Guidance
Programme:
Technology appraisal guidance
Published:
24 November 2022
Luspatercept for treating anaemia caused by myelodysplastic syndromes (terminated appraisal) (TA844)
Product type:
Guidance
Programme:
Technology appraisal guidance
Published:
24 November 2022
Luspatercept for treating anaemia in non-transfusion dependent beta-thalassaemia [ID3870]
Status:
Awaiting development
Programme:
Technology appraisal guidance
Expected publication date:
TBC
Lusutrombopag for treating thrombocytopenia in people with chronic liver disease needing a planned invasive procedure (TA617)
Product type:
Guidance
Programme:
Technology appraisal guidance
Published:
8 January 2020
Marstacimab for treating severe haemophilia A or B in people 12 years and over with inhibitors to factor-replacement therapy [TSID12143]
Status:
Awaiting development
Programme:
Technology appraisal guidance
Expected publication date:
TBC
Marstacimab for treating severe haemophilia A or severe haemophilia B in people 12 years and over [ID6342]
Status:
In development
Programme:
Technology appraisal guidance
Expected publication date:
18 June 2025
Mepolizumab for treating severe hypereosinophilic syndrome (terminated appraisal) (TA846)
Product type:
Guidance
Programme:
Technology appraisal guidance
Published:
29 November 2022
MIM8 for preventing bleeding episodes in haemophilia A in people 1 year and over [ID6400]
Status:
Awaiting development
Programme:
Technology appraisal guidance
Expected publication date:
TBC
Momelotinib for treating myelofibrosis-related splenomegaly or symptoms (TA957)
Product type:
Guidance
Programme:
Technology appraisal guidance
Published:
20 March 2024
Mozafancogene autotemcel for treating Fanconi anaemia in people 1 to 17 years [ID12203]
Status:
Awaiting development
Programme:
Technology appraisal guidance
Expected publication date:
TBC
Olezarsen for treating familial chylomicronaemia syndrome [TSID11993]
Status:
Awaiting development
Programme:
Technology appraisal guidance
Expected publication date:
TBC
OTL-101 for treating adenosine deaminase deficiency–severe combined immunodeficiency [ID1152]
Status:
Awaiting development
Programme:
Highly specialised technologies guidance
Expected publication date:
TBC
Pegcetacoplan for treating paroxysmal nocturnal haemoglobinuria (TA778)
Product type:
Guidance
Programme:
Technology appraisal guidance
Published:
9 March 2022
Pernicious anaemia
Status:
Awaiting development
Expected publication date:
TBC
Plozasiran for treating familial chylomicronaemia syndrome [ID6593]
Status:
Awaiting development
Programme:
Technology appraisal guidance
Expected publication date:
TBC
Ravulizumab for treating atypical haemolytic uraemic syndrome (TA710)
Product type:
Guidance
Programme:
Technology appraisal guidance
Published:
23 June 2021
Ravulizumab for treating paroxysmal nocturnal haemoglobinuria (TA698)
Product type:
Guidance
Programme:
Technology appraisal guidance
Published:
19 May 2021
Ravulizumab for untreated thrombotic microangiopathy after a haematopoietic stem cell transplant in people aged 28 days and over [TSID10642][ID6319]
Status:
Awaiting development
Programme:
Technology appraisal guidance
Expected publication date:
TBC
Rilzabrutinib for treating persistent or chronic immune thrombocytopenia in people aged 12 and over [ID6395]
Status:
Awaiting development
Programme:
Technology appraisal guidance
Expected publication date:
TBC
Rivogenlecleucel for treating haematological non-malignant diseases in children and young people undergoing haploidentical haematopoietic stem cell transplant [ID1496]
Status:
In development
Programme:
Technology appraisal guidance
Expected publication date:
TBC
Romiplostim for the treatment of chronic immune thrombocytopenia (TA221)
Product type:
Guidance
Programme:
Technology appraisal guidance
Last updated:
26 October 2018
Published:
27 April 2011
Ropeginterferon alfa-2b for treating polycythaemia vera without symptomatic splenomegaly [ID1596]
Status:
In development
Programme:
Technology appraisal guidance
Expected publication date:
TBC
Roxadustat for treating symptomatic anaemia in chronic kidney disease (TA807)
Product type:
Guidance
Programme:
Technology appraisal guidance
Published:
13 July 2022
Sebetralstat for treating acute attacks of hereditary angioedema in people aged 12 and over [ID6284]
Status:
In development
Programme:
Technology appraisal guidance
Expected publication date:
17 December 2025
Secukinumab for treating giant cell arteritis in people 50 years and over [TSID12163]
Status:
Awaiting development
Programme:
Technology appraisal guidance
Expected publication date:
TBC
Sickle cell disease (QS58)
Product type:
Quality standard
Published:
10 April 2014
Sickle cell disease: managing acute painful episodes in hospital (CG143)
Product type:
Guidance
Programme:
Clinical guideline
Published:
27 June 2012
Spectra Optia for automatic red blood cell exchange in people with sickle cell disease (MTG28)
Product type:
Guidance
Programme:
Medical technologies guidance
Published:
2 March 2016
Spectra Optia for plasma exchange, (MT828)
Status:
Topic selection
Programme:
Medical technologies guidance
Expected publication date:
TBC
Subcutaneous C1-esterase inhibitor for preventing recurrent attacks of hereditary angioedema in people 12 years and over [TSID11891]
Status:
Topic selection
Programme:
Technology appraisal guidance
Expected publication date:
TBC
Subcutaneous efgartigmod with recombinant human hyaluronidase PH20 for treating primary immune thrombocytopenia [TSID11977]
Status:
Awaiting development
Programme:
Technology appraisal guidance
Expected publication date:
TBC
Subcutaneous ravulizumab for treating paroxysmal nocturnal haemoglobinuria or atypical haemolytic uraemic syndrome [TSID11820]
Status:
Topic selection
Programme:
Technology appraisal guidance
Expected publication date:
TBC
Suspected sepsis: recognition, diagnosis and early management
Status:
In development | In consultation
Programme:
NICE guideline
Consultation end date:
18 July 2025
Expected publication date:
19 November 2025
Treosulfan with fludarabine before allogeneic stem cell transplant for people aged 1 month to 17 years with non-malignant diseases (terminated appraisal) (TA945)
Product type:
Guidance
Programme:
Technology appraisal guidance
Published:
30 January 2024
Treosulfan with fludarabine for non-malignant disease before allogeneic stem cell transplant [ID1540]
Status:
Awaiting development
Programme:
Technology appraisal guidance
Expected publication date:
TBC
Vadadustat for treating symptomatic anaemia in adults having dialysis for chronic kidney disease (TA1035)
Product type:
Guidance
Programme:
Technology appraisal guidance
Published:
23 January 2025
Valoctocogene roxaparvovec for treating severe haemophilia A [ID3806]
Status:
Awaiting development
Programme:
Technology appraisal guidance
Expected publication date:
TBC
Veverimer for treating metabolic acidosis in chronic kidney disease [ID3832]
Status:
Topic selection
Programme:
Technology appraisal guidance
Expected publication date:
TBC
Vitamin B12 deficiency in over 16s: diagnosis and management (NG239)
Product type:
Guidance
Programme:
NICE guideline
Published:
6 March 2024
Vonicog alfa for preventing haemorrhage in people with von Willebrand disease when desmopressin is ineffective or not suitable [ID6272]
Status:
Topic selection
Programme:
Health technology evaluation
Expected publication date:
TBC

Quality standards

Indicators

Get support from NICE

Learn how we evaluate technologies

Register your product

Find published and proposed evaluations

Our programmes

Get involved

What we do

Into practice

Who we are

Blood conditions Products

Showing 82 products